Study reveals that reversible chemical modifications can inhibit pyruvate kinase and affect its variants differently, ...

A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled "Dual targeting of oncogenic microtubules and mitochondria in PDAC." In this study led by first author ...

Cancer is one of the leading causes of death worldwide, marked by the uncontrolled growth of abnormal cells. What makes it ...

A new research paper was published in Volume 13 of Oncoscience on January 28, 2026, titled “Dual targeting of oncogenic ...

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Two new lines of brain research are testing whether aging cells can be nudged into working more like young ones. In one study ...

Researchers identify beta catenin protein degradation as a therapeutic vulnerability in B cell acute lymphoblastic leukaemia, supporting the repurposing of glycogen synthase kinase 3 beta inhibitors.

CAR T-cell therapy, considered one of the most promising breakthroughs in cancer treatment, works by harnessing the patient’s ...

Most cells in the human body exist in complex three-dimensional environments, yet they are still commonly studied on flat plastic dishes. These two-dimensional cultures distort cell behavior, limiting ...